Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241736 | 1.00 | NPC1 (0.36) | NPC1RAB9ALMNAMEN1KMT2A | |
| SCHEMBL241737 | 0.86 | MEN1 (0.43) | NPC1RAB9ALMNAMEN1KMT2A | |
| SCHEMBL2116092 | 0.83 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1KDM4ECYP1A2 | |
| SCHEMBL244487 | 0.83 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1KDM4ECYP1A2 | |
| SCHEMBL2137284 | 0.82 | MEN1 (0.36) | MEN1KMT2AALDH1A1KDM4ECYP1A2 | |
| SCHEMBL1970697 | 0.82 | MEN1 (0.36) | MEN1KMT2AALDH1A1KDM4ECYP1A2 | |
| SCHEMBL18279539 | 0.80 | NPC1 (0.35) | NPC1RAB9ALMNAALDH1A1KDM4E | |
| SCHEMBL598483 | 0.79 | NPSR1 (0.48) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL554289 | 0.79 | NPSR1 (0.48) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7772643 | 0.79 | NPSR1 (0.48) | LMNAMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11026927-B2 | Pharmaceutical combination comprising a selective S1P1 receptor agonist | ACTELION PHARMACEUTICALS LTD (CH) | 2021-06-08 | — | — | US | claimed |
| US-20210145755-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | ARBOR PHARMACEUTICALS, LLC | 2021-05-20 | — | — | US | claimed |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | ARBOR PHARMACEUTICALS, LLC (US) | 2021-03-09 | — | — | US | claimed |
| US-20200246271-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2020-08-06 | — | — | US | claimed |
| US-10716760-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | ARBOR PHARMACEUTICALS, LLC (US) | 2020-07-21 | — | — | US | claimed |
| EP-2887935-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | XenoPort, Inc. (US) | 2015-07-01 | — | — | EP | claimed |
| WO-2014031894-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| WO-2014031897-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF (N,N- DIETHYLCARBAMOYL)METHYL METHYL|(2E)BUT-2-ENE-1,4-DIOATE | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | claimed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | claimed |
| US-20260007627-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4215191-A1 | COMPOSITION COMPRISING A FUMARATE FOR USE IN A METHOD OF TREATING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20220072117-A1 | Dimethyl Fumarate and Vaccination Regimens | BIOGEN MA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11246850-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| US-20130295169-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | BIOGEN MA INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130216615-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | BIOGEN IDEC MA INC. | 2013-08-22 | — | — | US | disclosed |
| WO-2013119677-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | BIOGEN IDEC MA INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246271-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | NPC1 3828/4885RAB9A 2454/4885LMNA 4876/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | NPC1 4131/4885RAB9A 3060/4885LMNA 4576/4885 |
| US-20210145755-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | NPC1 3828/4885RAB9A 2454/4885LMNA 4876/4885 |
| US-20260007627-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FH, SLC6A6, SLC6A13 | NPC1 290/4885RAB9A 3405/4885LMNA 1608/4885 |
| US-11246850-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | NPC1 559/4885RAB9A 4537/4885LMNA 3109/4885 |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | FH, FAH, DHFR | NPC1 3263/4885RAB9A 4591/4885LMNA 2518/4885 |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | NPC1 559/4885RAB9A 4537/4885LMNA 3109/4885 |
| US-20130216615-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | FH, FAH, MGMT | NPC1 1456/4885RAB9A 3279/4885LMNA 3411/4885 |
| US-20220072117-A1 | Dimethyl Fumarate and Vaccination Regimens | FH, HLA-DRB1, SDHB | NPC1 2876/4885RAB9A 2823/4885LMNA 4083/4885 |
| US-20130295169-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | FH, FAH, MGMT | NPC1 1456/4885RAB9A 3279/4885LMNA 3411/4885 |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | FH, MGMT, BHMT2 | NPC1 3828/4885RAB9A 2454/4885LMNA 4876/4885 |
| US-10716760-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | FH, MGMT, BHMT2 | NPC1 3828/4885RAB9A 2454/4885LMNA 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.